Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to complete initial human studies.

The San Diego-based antibody company was formed in January 2019 as part of Frazier Healthcare Partners’ company creation activities. In August, Frazier led Lassen Therapeutics’ $31 million series A round, which had participation from Alta Partners, Longwood Fund and DC Investment Partners...